A Phase 1 Dose-Escalation Study of Apatorsen (OGX-427), an Antisense Inhibitor Targeting Heat Shock Protein 27 (Hsp27), in Patients with Castration Resistant Prostate Cancer and Other Advanced Cancers

Apatorsen is an antisense inhibitor of heat shock protein 27 (Hsp27), a chaperone protein that regulates cell survival via androgen receptor and other signaling pathways. A Phase 1 study was conducted in patients with CRPC and other cancers known to overexpress Hsp27. Apatorsen had an acceptable safety profile and a MTD was not defined. Clinical activity at doses ≥400 mg was suggested by effects on stable measurable disease, declines in PSA, other tumor markers, and CTCs.

from Cancer via ola Kala on Inoreader http://ift.tt/1oytFAB
via IFTTT